SUMMIT, N.J., May 3, 2021 /PRNewswire/ — Seqirus, a global leader in influenza prevention, presented new Phase 3 clinical data demonstrating that the company’s cell-based quadrivalent seasonal influenza vaccine (QIVc) was as safe and immunogenic as a standard quadrivalent seasonal influenza vaccine (QIV) in children six months through <4 years of age during the U.S. 2019/20 influenza season.1 These data were presented at the Pediatric Academic Society (PAS) Virtual Annual Meeting on May 1, 2021.
“There is a significant disease burden of influenza for young children, and the CDC recognizes this population as one of high-risk for serious complications from the flu,” said Brandon J. Essink, MD, CPI, Medical Director at Meridian Clinical Research and principal investigator of the study.2 “The results of this study provide evidence for the benefit of QIVc for pediatric patients, adding to a strong body of evidence in support of cell-based manufacturing for influenza vaccines.”
The Centers for Disease Control and Prevention (CDC) recommends seasonal influenza vaccine every year as the best way to prevent influenza for everyone six months of age and above without contraindications.3 Children younger than five years of age, especially those under two years of age, are at high risk of developing serious influenza-related complications.2 Since 2010, estimated annual influenza-related hospitalizations among children younger than five years of age have ranged from 7,000-26,000 in…
